Hemophilia

Pasteurized Clotting Factor Effective, Virus-Free

Published in Blood Weekly, April 12th, 2001

by Sonia Nichols, staff medical writer - A current study reports Monoclate-P, a pasteurized factor VIII (FVIII) protein used for treating type A hemophiliacs, is effective and free of common bloodborne viruses.

The report, published in Haemophilia, indicates Monoclate-P can be safely tolerated in pediatric patients with few adverse effects.

Results of the study were based on an open-label clinical trial of 30 patients. Eighteen (severe) and 12 (moderate) hemophiliacs were given Monoclate-P for up to 34 months, during which time they were monitored for hepatitis viruses and human immunodeficiency virus (HIV).

None of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-04-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry